Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Denosumab for Prevention of Post-Teriparatide Bone Loss in Premenopausal Women With Idiopathic Osteoporosis (IOP)

NCT02049866 is registered in ClinicalTrials.gov with Elizabeth Shane as lead sponsor.

NCT NCT02049866
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02049866 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Denosumab for Prevention of Post-Teriparatide Bone Loss in Premenopausal Women With Idiopathic Osteoporosis (IOP)
Lead sponsor
Elizabeth Shane
Phase
Phase 2
Overall status
Completed
Start date
November 19, 2014
Completion date
December 23, 2021
Enrollment
33 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

adult idiopathic generalized osteoporosis